Barclays’s Amylyx Pharmaceuticals AMLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $835K | Sell |
130,274
-7,131
| -5% | -$45.7K | ﹤0.01% | 2769 |
|
|
2025
Q1 | $486K | Buy |
137,405
+62,560
| +84% | +$221K | ﹤0.01% | 2863 |
|
|
2024
Q4 | $282K | Sell |
74,845
-9,727
| -12% | -$36.6K | ﹤0.01% | 3356 |
|
|
2024
Q3 | $274K | Buy |
84,572
+40,319
| +91% | +$131K | ﹤0.01% | 3330 |
|
|
2024
Q2 | $84K | Sell |
44,253
-62,589
| -59% | -$119K | ﹤0.01% | 3454 |
|
|
2024
Q1 | $304K | Buy |
106,842
+15,963
| +18% | +$45.4K | ﹤0.01% | 3122 |
|
|
2023
Q4 | $1.34M | Buy |
90,879
+65,180
| +254% | +$959K | ﹤0.01% | 2419 |
|
|
2023
Q3 | $470K | Sell |
25,699
-52,285
| -67% | -$956K | ﹤0.01% | 2589 |
|
|
2023
Q2 | $1.68M | Sell |
77,984
-3,922
| -5% | -$84.6K | ﹤0.01% | 1842 |
|
|
2023
Q1 | $2.4M | Buy |
81,906
+43,411
| +113% | +$1.27M | ﹤0.01% | 1524 |
|
|
2022
Q4 | $1.42M | Buy |
38,495
+19,695
| +105% | +$728K | ﹤0.01% | 1861 |
|
|
2022
Q3 | $529K | Buy |
18,800
+18,225
| +3,170% | +$513K | ﹤0.01% | 2563 |
|
|
2022
Q2 | $11K | Sell |
575
-984
| -63% | -$18.8K | ﹤0.01% | 4279 |
|
|
2022
Q1 | $20K | Buy |
+1,559
| New | +$20K | ﹤0.01% | 4323 |
|